Objective: Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs. We sought to determine whether MVC has differential effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy.
Introduction
HIV-induced immune dysfunction is not completely restored by antiretroviral therapy (ART) [1] . Elevated soluble markers of inflammation and coagulation during ART predict non-AIDS events [2] . T-cell populations may also remain numerically abnormal and the CD4 þ : CD8 þ T-cell ratio often fails to normalize to greater than 1 despite viral suppression [3] . The likelihood of attaining a CD4 þ : CD8 þ T-cell ratio greater than 1 may be influenced by the ART regimen [4] , and a low ratio independently predicts non-AIDS-defining events and death [3, 5] . Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs [6, 7, 8] .
We recently reported less bone loss in 48 weeks of an initial MVC-containing regimen compared with a tenofovir disoproxil fumarate (TDF)-containing combination in AIDS Clinical Trials Group (ACTG) study A5303 [9] . Virologic efficacy was not different between the two arms [9] . Here, we present the immunology results. The immunology objective of A5303 was to determine whether the effects of MVC on inflammation, immune activation, and T-cell reconstitution in the context of initial ART could be differentiated from the effects of TDF.
Methods ACTG A5303 was a phase II, prospective, double-blind, placebo-controlled, multicenter, 48-week study of an experimental regimen [MVC arm: darunavir/ritonavir (DRV/r) 800/100 mg þ emtricitabine (FTC) 200 mg þ MVC 150 mg daily] compared with a standard of care regimen (TDF arm: DRV/r 800/100 mg þ FTC 200 mg þ TDF 300 mg daily) in antiretroviral (ARV)naïve adults infected with C-C chemokine receptor type 5 (CCR5)-tropic HIV-1. HIV-1 tropism was determined using Trofile (Monogram Biosciences, San Francisco, California, USA). Eligibility required HIV-1 RNA more than 1000 copies/ml and no evidence of active hepatitis B. Randomization was stratified by plasma HIV-1 RNA less than or at least 100 000 copies/ml and age less than or at least 30 years. Details for the study designs were described in the primary manuscript [9] . The Institutional Review Board of each study site approved the protocol. Each participant provided their written informed consent (Clinicaltrials.gov identifier NCT01400412). The study enrolled 262 participants in the United States.
Polychromatic flow cytometry was performed in batch on week 0 and 48 cryopreserved peripheral blood mononuclear cells (PBMCs) from each participant. In brief, cells were stained for viability with Aqua Live/Dead (Life Technologies, Eugene, Oregon, USA) followed by cell staining using fluorochrome-conjugated monoclonal antibodies (BD Biosciences, San Jose, California, USA; BioLegend, San Diego, California, USA; eBiosciences, Inc., San Diego, California, USA). PBMC were stained for T-cell subsets (CD3/CD4, CD3/CD8) and associated markers of immune activation (CD38/HLA-DR), senescence (CD57/CD28), and T-regulatory (CD25/ FOXP3) cells. In a separate tube, PBMC were stained for markers of monocyte subsets (CD14/CD16/CCR2/ CX3CR1), B cells (CD19/FcRL4), and natural killer (NK) cell subsets (CD56/CD16). All tubes were fixed in 1% formaldehyde and analyzed within 24 h on an LSRFortessa flow cytometer (BD Biosciences) using BD FACSDiva software v7.0. Analysis of flow cytometry data was performed using FlowJo software (FlowJo, LLC, Ashland, Oregon, USA).
Frozen\thawed week 0 and 48 EDTA plasma samples were analyzed using ELISA kits for quantification of soluble(s) CD14, sCD163, IFNg-induced protein-10, soluble tumor necrosis factor receptor II, and highsensitivity IL-6 (all Quantikine; R & D Systems, Inc., Minneapolis, Minnesota, USA). D-dimer was measured in citrate plasma using an ELISA kit from Diagnostica Stago, Inc. (Parsippany, New Jersey, USA). All ELISAs were run according to the manufacturers' protocols.
Statistical analyses
All analyses were as treated and included only participants who remained on their randomized MVC or TDF component by week 48 without an interruption in treatment of more than 10 weeks with available data for both baseline and week 48. Participants with missing data because of insufficient blood samples, data errors, or lab errors were further excluded from the analyses.
Wilcoxon signed-rank tests were used to test for withintreatment arm changes greater than zero; 95% confidence intervals for median changes within-treatment arm were estimated using distribution-free method via percentiles. Stratified Wilcoxon rank sum tests were used to test for treatment arm differences, stratified by the age stratum (<30 vs. !30 years). Among participants with an inverted CD4 þ : CD8 þ ratio (ratio <1) at baseline, treatment arm differences in the CD4 þ : CD8 þ ratio normalization (ratio >1) [4] over 48 weeks were assessed with Fisher's tests. In addition, proportions of participants with a CD4 þ : CD8 þ ratio greater than 0.4 [5] were also evaluated with Fisher's test. Changes in soluble biomarkers and CD4 þ /CD8 þ cell counts were assessed on the absolute changes from baseline to week 48, whereas changes in percentage expression for cellular biomarkers were assessed as percentage change [i.e., 100% Â (week 48 À week 0) / week 0].
All statistical tests were two sided and presented with nominal P values. To account for the large number of soluble and cellular markers tested, P values for treatment arm comparisons for these markers were conservatively interpreted at the 0.5% nominal level of significance; conclusions regarding P values between 0.05 and 0.005 were tempered. Given the prior data with MVC with respect to changes in CD4 þ T-cell count changes, inferences regarding CD4 þ , CD8 þ , and their ratio were interpreted at a conventional 5% level. Analyses were conducted using SAS statistical software 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Results
A total of 230 participants were in the as-treated population (119 in the MVC arm and 111 in the TDF arm). There were 9% women, 44% white, 31% black, and 22% Hispanic. The median age at baseline was 33 years, median HIV-1 RNA was 4.5 log 10 copies/ml and median CD4 þ cell count was 390 cells/ml.
CD4 R and CD8 R T-cell counts A greater CD4 þ T-cell count increase from baseline to week 48 was observed in the MVC arm [median change 234 cells/ml (Q1, Q3: 131, 327)] than in the TDF group [188 cells/ml (94 304); P ¼ 0.036]. Although significant within-arm decreases in CD8 T-cell count were observed over 48 weeks in TDF arm [median change À109 cells/ml (À340 59); P < 0.001], these were not apparent with MVC [À6 cells/ml (À252 175); P ¼ 0.51] between-arm comparison (P ¼ 0.008). In turn, a smaller increase in the CD4 þ : CD8 þ ratio from baseline to week 48 was observed in the MVC arm than in the TDF arm (P ¼ 0.003); median (Q1, Q3) change 0.26 (0.13, 0.43) in the MVC arm compared with 0.39 (0.21, 0.54) in the TDF arm (Table 1) .
Among 215 participants with a CD4 þ : CD8 þ ratio less than 1 at baseline (n ¼ 110 in MVC and n ¼ 105 in TDF), 15 and 36% of the participants in the MVC arm and TDF arm, respectively, had a normalized CD4 þ : CD8 þ ratio (ratio >1) at week 48 (P < 0.001). Using a CD4 þ : CD8 ratio cut-off of 0.4, there was no significant difference between the two arms (P ¼ 0.93): 90 and 88% on MVC vs. TDF arm with a ratio greater than 0.4 at week 48.
Soluble biomarkers
With the exception of IL-6 and soluble CD14 (sCD14), significant declines in all soluble biomarkers from baseline to week 48 in both treatment arms were apparent (P < 0.001). For IL-6 and sCD14, declines were apparent in the MVC arm (P ¼ 0.007 and 0.001, respectively) but not the TDF arm (P ¼ 0.12 and 0.41, respectively). Differences between the two treatment arms were not apparent in any of these soluble biomarkers (P > 0.10; Table 1 ).
Cellular biomarkers (CD4 and CD8 subsets, monocytes, B cells, and natural killer cells)
Although significant within-group changes in a range of the CD4, CD8, or monocyte subsets examined were apparent, there was no evidence of differences between MVC and TDF arms (P > 0.05; Table 2 ). Of note, although the treatment arm difference in percentage increase in %CD56HI/CD16-(NK cells) approached our conservative threshold for statistical significance (P ¼ 0.007; median percentage change: 4% (À23, 64%) in the MVC arm compared with 30% (À2, 89%) in the TDF arm, the magnitude of these increases on an absolute scale were small (median absolute change 0.2 vs. 1.0%).
Discussion
In this randomized trial, initiating ART with a MVCcontaining regimen resulted in significant declines in all soluble markers (IL-6, induced protein-10, soluble tumor necrosis factor receptor II, sCD14, D-dimer, and sCD163) from weeks 0 to 48. Significant declines in the soluble biomarkers occurred in the TDF arm with the exception of IL-6 and sCD14. Overall, no significant differences were detected between MVC and TDF in the decline in any soluble marker in our study. Changes from baseline to week 48 in cellular markers of T-cell activation and senescence, and in monocyte, B cell, and NK cell populations were also not different between MVC and TDF. We saw a treatment arm difference in %CD56HI/ CD16-(NK cells) that was marginally significant, but the magnitudes of the increases were too small to be considered clinically meaningful. Given the comparable virologic efficacy of the MVC and TDF regimens in our study [9] , the immunologic changes in both arms were likely driven mainly by suppression of viral replication. Of note, ACTG A5260s also found no significant decline in IL-6 and sCD14 levels among participants who received TDF/FTC plus DRV/r, although both markers declined significantly in the TDF/FTC plus raltegravir arm of the study [10] .
Our results demonstrate that MVC produces a greater numerical increase in CD4 þ T cells than TDF in initial ART (difference in median increase of 46 cells/ml), consistent with the greater improvement reported with MVC relative to efavirenz [11] . Metaregression of data from 17 clinical trials involving treatment-experienced participants also demonstrated that MVC use was associated with an additional gain of 30 CD4 þ T cells/ ml at 24 weeks [12] . An effect of MVC on CD4 þ T-cell counts was previously demonstrated even when virologic suppression was not achieved [13] .
CD8 þ T-cell count decreased significantly in the TDF arm but not the MVC arm. A potential explanation for this is that CD8 þ T cells are more likely to express CCR5 than CD4 þ T cells in circulation [6] ; hence, CCR5 blockage may preferentially prevent trafficking of CD8 þ cells out of circulation, and result in a differential expansion of CD8 þ T cells. Consistent with this, although the CD4 þ : CD8 þ T-cell ratio increased in both arms, the improvement was significantly smaller in the MVC arm. Further, among study participants with an inverted CD4 þ : CD8 þ ratio (ratio <1) at baseline, normalization to a ratio greater than 1 occurred less frequently in the MVC arm. Although the clinical implications of these findings are uncertain, inversion of the CD4 þ : CD8 þ ratio is a hallmark of immunosenescence and an independent predictor of mortality [14] . Nevertheless, our findings on the CD4 þ : CD8 þ T-cell repopulation should be interpreted with caution as participants were followed for 48 weeks only, and there is no evidence that MVC increases long-term morbidity or mortality. Using a CD4 þ : CD8 þ ratio cut-off of 0.4 at week 48, which has been linked with risk of non-AIDS events during ART [3, 5] , we found no significant difference between MVC and TDF. Some investigators recently reported a strong association between use of an integrase strand transfer inhibitor in initial ART and normalization of the CD4 þ : CD8 þ T-cell ratio [4] . Future studies should delineate further how contemporary ART regimens differ in their effects on the CD4 þ : CD8 þ T-cell ratio and also define the clinical consequences.
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